Status:
UNKNOWN
Molecular Determinants for Therapy Response on Renal Cell Carcinoma
Lead Sponsor:
Heidelberg University
Conditions:
Renal Cell Carcinoma
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Aim of the scientific analysis is to find biological factors (biomarkers) allowing a prediction of disease progression and a better choice of therapy. After diagnosis the kidney and the tumor will be ...
Detailed Description
Aim of this study is to perform a profound molecular analysis of the tumor before beginning therapy and after failure of the approved targeted first-and second line therapy (standard therapy). The tum...
Eligibility Criteria
Inclusion
- Minimum Age: 18 Years Maximum Age: no maximum age
- metastatic lesions easy of access for puncture for specimen storage
- histological subtype: clear-cell renal cancer
- no contraindications against systemic therapy
- indication for systemic therapy given
Exclusion
- preexisting mental illness
- further active malignancy
- patients with increased risk of bleeding and/or wound healing disorder
- patients who are not legally competent or unable to consent
- contraindication for surgical intervention
Key Trial Info
Start Date :
May 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2018
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT02208128
Start Date
May 1 2014
End Date
February 1 2018
Last Update
August 4 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Urological Department of the University Hospital Heidelberg
Heidelberg, Germany, 69120